RSH - Respiri Limited

[greggles]

Respiri Limited has been keeping the good news coming. Today it announced that it has successfully completed the functional demonstration prototype of its second generation AirSonea® wheeze monitor and the share price jumped on the news. There's lots of confidence in this one at the moment. Huge market and innovative product.

 

[pixel]

I got burned by its previous incarnation. iSONEA had also lots of good news, prototypes and approvals in the pipeline. What happened to the Wholter, for eg?
In recent reports, I still can't find any operational revenue, let alone profit.

 

[greggles]

I got burned by its previous incarnation. iSONEA had also lots of good news, prototypes and approvals in the pipeline. What happened to the Wholter, for eg?
In recent reports, I still can't find any operational revenue, let alone profit.

It's a real risk to hold these kind of stocks long term unless you really understand the market and their technology and products. That being said, the ride up can be breathtaking, so I think the smart approach is to buy in for the ride up then maybe sell some after profits have been made and free carry the rest as a risk mitigation strategy. That way you can profit further and buy back in if the company is on a winner or sell out and walk away if it misses.

 

[pixel]

... and it seems that - or something like it - is exactly what punters did today
How many of them would have been participants in the recent 8cps fund raiser?

 

[greggles]

My caution with RSH has proven to be well founded. After peaking at 16.5c in early May, the RSH share price then proceeded to decline to 7c over the next four months. The excitement wore off and those who bought in hoping that it was going to the moon beat a hasty exit when they realised it wasn't going to be that easy.

That being said, it may have bottomed out at 7c, at least in the short term. Today Respiri announced a manufacturing agreement with SRX Global for the production of its next generation breath and asthma wheeze detection sensor. Manufacturing agreements mean that production can't be too far away and hopefully revenue won't be too far behind that.

RSH is up 19.48% to 9.2c today on volume of around 2 million shares.

 

[Dona Ferentes]

Respiri came out of a trading halt on Friday morning after announcing it had signed a sales and distribution deal with Indian pharmaceutical giant Cipla under which the global group will initially order 2000 of the "wheezo" units for sale to doctors and pharmacies in Australia and New Zealand. Shares in Respiri initially bounced more than 50 per cent to 16.5¢ before giving up most of those gains by late morning,....

The "wheezo" device is an egg-shaped product that is held up to a person's windpipe and monitors the rate of wheezing. It is connected to an app that collects the data and gives a readout of wheezing rates. Respiri has had a chequered history on the ASX and has spent years trying to commercialise the device.

Respiri chief executive Marjan Mikel said on Friday that a large amount of work had been undertaken over the past few months to reduce the production cost of the "wheezo" devices. The Cipla agreement would generate gross product margins of between 30 per cent and 40 per cent from the start of calendar 2021.
It would take time to win over the medical community.

"We're up for the challenge,'' he said. "That's certainly why we needed an 800-pound gorilla in the form of Cipla.''

Mr Mikel said Cipla's sales force in Australia had coverage of 15,000 doctors and 4000 pharmacies.
There were 2.7 million sufferers of asthma in Australia and Respiri's business model was based on trying to reach 2 per cent penetration over 18 months.

Mr Mikel arrived as the new chief executive in December and said the group needed to show a track record to investors to build credibility.

"The company has had a chequered history and a lot of false starts,'' he said. He was trying to bring a sharper commercial focus to the business. "The organisation was in perpetual R&D mode,'' he said.

Mr Mikel emphasised that Respiri was a medical device company and that widespread adoption of the "wheezo" as part of asthma monitoring programs would be gradual. "It's going to require a behavioural change on behalf of the medical community," he said.

 

[Dona Ferentes]

and signed with ZipPay (Z1P)

"Our Agreement with ZIP provides asthmatic patients seeking access to our platform additional financial flexibility when making these important healthcare decisions relating to improvements in the management of their disease"

 

[Dona Ferentes]

The company has created an egg-shaped device which a person holds up to their trachea and records their deep breathing for 30 seconds. The recording is then sent via bluetooth to an app on the person’s phone, which utilises artificial intelligence to analyse the sound and detect an asthma sufferers “wheeze rate”. It is designed to help a patient and their doctor manage their asthma by providing data on a person’s condition, versus relying on a patient’s own account of their symptoms.

By analysing the data, a doctor is able to determine if a person’s asthma was made worse on a particular day because there was a high pollen count, or bushfire smoke, or even a sudden cool change.

Having started selling its Wheezo device through pharmacies in Australia late last year, Respiri Health is now also planning to launch in the US. On Tuesday, it announced that it had received 510(k) clearance from the US FDA, thereby permitting Wheezo to sell and market its class two medical device, along with the accompanying app.

 

[frugal.rock]

Interesting reversal on the chart, for reasons unknown to me.
A push to 10 cent before closing the gap?
Or a reversal back to 8 cent then an attempt at 10 cent again?
Dunno, heads or tails.

 

[Garpal Gumnut]

I did look at RSH a while ago but remembered the old adage " If you want to know what the weather is like, look out the window. "

I ran it past my quack then and she rolled her eyes.

I suppose if they get 2-3% of all people with the asthma they will make a quid, but getting them is the problem.

Chartwise I'd be looking at a filling of that gap as you pointed out @frugal.rock

Here at the hotel over 50% at the public bar wheeze from the smokes and use puffers and I haven't seen any of them holding egg shaped gizmos to their necks.

gg

 

[kenny]

Long time since this has been on anyone's radar. Recent six months has seen more adoption. Video interview is a good summary by CEO;

 

[farmerge]

Long time since this has been on anyone's radar. Recent six months has seen more adoption. Video interview is a good summary by CEO;

View attachment 153719

Complete newy RSH to me But that is only one of so many. That's what I like about the Comp. seeing all the penny dreadful seeing the light of day. Most wouldn't get a second glance.